644 related articles for article (PubMed ID: 27114417)
1. Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.
Jung CH; Um SH; Kim TH; Yim SY; Suh SJ; Yim HJ; Seo YS; Choi HS; Chun HJ
Gut Liver; 2016 Sep; 10(5):808-17. PubMed ID: 27114417
[TBL] [Abstract][Full Text] [Related]
2. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.
Moon C; Jung KS; Kim DY; Baatarkhuu O; Park JY; Kim BK; Kim SU; Ahn SH; Han KH
Dig Dis Sci; 2015 Feb; 60(2):573-81. PubMed ID: 25236421
[TBL] [Abstract][Full Text] [Related]
3. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial.
Huang JF; Yu ML; Huang CF; Chiu CF; Dai CY; Huang CI; Yeh ML; Yang JF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Wang LY; Chuang WL
J Hepatol; 2011 Feb; 54(2):219-26. PubMed ID: 21056500
[TBL] [Abstract][Full Text] [Related]
5. Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C.
Honda T; Ishigami M; Masuda H; Ishizu Y; Kuzuya T; Hayashi K; Itoh A; Hirooka Y; Nakano I; Ishikawa T; Urano F; Yoshioka K; Toyoda H; Kumada T; Katano Y; Goto H
J Gastroenterol Hepatol; 2015 Feb; 30(2):321-8. PubMed ID: 25091027
[TBL] [Abstract][Full Text] [Related]
6. [Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection].
Kang MJ; Jung EU; Park SW; Choi P; Kim JH; Park SJ; Park ET; Lee YJ; Lee SH; Seol SY
Korean J Hepatol; 2008 Sep; 14(3):318-30. PubMed ID: 18815455
[TBL] [Abstract][Full Text] [Related]
7. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
Shiffman ML; Ghany MG; Morgan TR; Wright EC; Everson GT; Lindsay KL; Lok AS; Bonkovsky HL; Di Bisceglie AM; Lee WM; Dienstag JL; Gretch DR
Gastroenterology; 2007 Jan; 132(1):103-12. PubMed ID: 17241864
[TBL] [Abstract][Full Text] [Related]
8. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
Harrison SA; Hamzeh FM; Han J; Pandya PK; Sheikh MY; Vierling JM
Hepatology; 2012 Aug; 56(2):464-73. PubMed ID: 22334369
[TBL] [Abstract][Full Text] [Related]
9. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
10. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.
Cardoso AC; Moucari R; Figueiredo-Mendes C; Ripault MP; Giuily N; Castelnau C; Boyer N; Asselah T; Martinot-Peignoux M; Maylin S; Carvalho-Filho RJ; Valla D; Bedossa P; Marcellin P
J Hepatol; 2010 May; 52(5):652-7. PubMed ID: 20346533
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
[TBL] [Abstract][Full Text] [Related]
13. [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].
Lee H; Choi MS; Paik SW; Kim JH; Kim DY; Lee JH; Koh KC; Yoo BC; Rhee JC; Song SM
Korean J Hepatol; 2006 Mar; 12(1):31-40. PubMed ID: 16565604
[TBL] [Abstract][Full Text] [Related]
14. Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment.
Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
Int J Infect Dis; 2011 Nov; 15(11):e740-6. PubMed ID: 21803628
[TBL] [Abstract][Full Text] [Related]
15. Virologic responses and tolerance of peginterferon alfa plus ribavirin treatment for patients with chronic hepatitis C virus infection in different age categories.
Yang Z; Lu Y; Xu Q; Chen X
Niger J Clin Pract; 2016; 19(1):133-9. PubMed ID: 26755232
[TBL] [Abstract][Full Text] [Related]
16. Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study.
Sidhu SS; Malhi NS; Goyal O; Singh R; Dutta U; Grover R; Sidhu JS; Nanda V; Saluja H; Bansal A; Singh G; Sehgal A; Kishore H; Sidhu S
Hepatol Int; 2017 May; 11(3):277-285. PubMed ID: 28361300
[TBL] [Abstract][Full Text] [Related]
17. [Durability of sustained virologic response in chronic hepatitis C: analysis of factors related to relapse after sustained virologic response with peginterferon plus ribavirin combination therapy].
Lee JE; Yoon NR; Kim JD; Song MJ; Kwon JH; Bae SH; Choi JY; Jeong SW; Yoon SK
Korean J Gastroenterol; 2011 Mar; 57(3):173-9. PubMed ID: 21519165
[TBL] [Abstract][Full Text] [Related]
18. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.
Vierling JM; Davis M; Flamm S; Gordon SC; Lawitz E; Yoshida EM; Galati J; Luketic V; McCone J; Jacobson I; Marcellin P; Muir AJ; Poordad F; Pedicone LD; Albrecht J; Brass C; Howe AY; Colvard LY; Helmond FA; Deng W; Treitel M; Wahl J; Bronowicki JP
J Hepatol; 2014 Apr; 60(4):748-56. PubMed ID: 24362076
[TBL] [Abstract][Full Text] [Related]
19. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
[TBL] [Abstract][Full Text] [Related]
20. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.
Rossignol JF; Elfert A; El-Gohary Y; Keeffe EB
Gastroenterology; 2009 Mar; 136(3):856-62. PubMed ID: 19135998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
